Is There a Role for Response-Adapted Treatment in Mantle Cell Lymphoma?

Matthew J. Matasar, MD, discusses the prospect of using minimal residual disease to guide treatment decisions in mantle cell lymphoma.

Related Videos
View All
Related Content